Is Mankind Pharma overvalued or undervalued?

As of 26 September 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued, with a PE ratio of 54.02, a Price to Book Value of 7.15, and an EV to EBITDA ratio of 31.27. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Mankind Pharma's PE ratio is significantly higher than Sun Pharma's 33.18 and Cipla's 22.45, both of which are considered attractive. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -13.96% compared to the Sensex's positive return of 2.93%. This underperformance further reinforces the conclusion that Mankind Pharma is overvalued in the current market environment.